Concepedia

Toshifumi Kajioka

TK

Statistics

Publications

4

Citations

172

H-Index

4

Active since

2005

Affiliations

EA Pharma (Japan)(Current)

Toho University

Hirosaki National Hospital

Fukuoka University Hospital

Kitasato University

Toshifumi Kajioka is an author at EA Pharma (Japan) specializing in inflammation, integrin inhibitors, and protein phosphorylation.

Publications per year

2005–2022

4

Publications

4

AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

Katsuyoshi Matsuoka, Mamoru Watanabe, Toshihide Ohmori et al. · The Lancet. Gastroenterology & hepatology · 2022 · 80 citations

Pharmacy, Clinical Sciences, Pharmacotherapy +12

GSK-3β Directly Phosphorylates and Activates MARK2/PAR-1

Shinichi Kosuga, Etsu Tashiro, Toshifumi Kajioka et al. · Journal of Biological Chemistry · 2005 · 58 citations · Full text

Life Sciences, Molecular Biology, Neuroscience +17

AJM300, a novel oral antagonist of α4‐integrin, sustains an increase in circulating lymphocytes: A randomised controlled trial in healthy male subjects

Hiroyuki Fukase, Toshifumi Kajioka, Ichiro Oikawa et al. · British Journal of Clinical Pharmacology · 2019 · 24 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

AJM300 (Carotegrast Methyl), an Oral Antagonist of α4-Integrin, as Induction Therapy for Patients with Moderately Active Ulcerative Colitis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase 3 Study

Katsuyoshi Matsuoka, Mamoru Watanabe, Toshihide Ohmori et al. · SSRN Electronic Journal · 2021 · 10 citations · Full text

Pharmacy, Clinical Sciences, Pharmacotherapy +13

1–4 of 4